Grifols (GIFLF) Share-based Compensation (2012 - 2022)
Grifols' (GIFLF) quarterly Share-based Compensation came in at -$3.5 million in Q4 2022, down 102.59% quarter-over-quarter from $136.3 million in Q4 2013.
Analysis
Grifols (GIFLF) Share-based Compensation (2012 - 2022) Analysis & Trends
Grifols (GIFLF) has reported Share-based Compensation for 3 consecutive years, with -$3.5 million the latest figure, recorded in Q4 2022.
- For the quarter ending Q4 2022, Share-based Compensation changed N/A year-over-year to -$3.5 million; the trailing twelve-month figure through Dec 2022 stood at -$3.5 million (changed N/A YoY), and the FY2022 full-year result was -$3.5 million, up 97.55% from the prior year.
- Share-based Compensation declined to -$3.5 million in Q4 2022 per GIFLF's latest filing, from $136.3 million in the prior quarter.
- Across five years, Share-based Compensation topped out at -$3.5 million in Q4 2022 and bottomed at -$3.5 million in Q4 2022.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 203.97 Bn | 189.99 Bn | 7.24 Bn | 247.00 Mn |
| 2 | Gilead Sciences | 178.74 Bn | 175.56 Bn | 6.22 Bn | 231.00 Mn |
| 3 | Vertex Pharmaceuticals | 130.73 Bn | 122.88 Bn | 2.84 Bn | 108.10 Mn |
| 4 | Regeneron Pharmaceuticals | 80.42 Bn | 72.42 Bn | 3.93 Bn | 243.00 Mn |
| 5 | Argenx Se | 60.40 Bn | 55.21 Bn | 1.37 Bn | - |
| 6 | Moderna | 57.65 Bn | 52.52 Bn | 52.00 Mn | 120.00 Mn |
| 7 | Alnylam Pharmaceuticals | 33.37 Bn | 30.07 Bn | 992.69 Mn | 86.63 Mn |
| 8 | Biogen | 32.15 Bn | 30.86 Bn | 1.96 Bn | 77.40 Mn |
| 9 | Roivant Sciences | 29.58 Bn | 29.58 Bn | 1.16 Mn | 83.34 Mn |
| 10 | Grifols | 7.54 Bn | 9.09 Bn | 3.33 Bn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2022 | -3.53 Mn |
| Dec 31, 2013 | 136.26 Mn |
| Dec 31, 2012 | 6.72 Mn |